Endolymphatic stromal myosis. Surgical and hormonal treatment of extensive abdominal recurrence 20 years after hysterectomy

Gloor, E; Schnyder, P.; Cikes, Matko; Hofstetter, Jacques; R, Cordey; Burnier, Francois; Knobel, Pierre

doi:10.1002/1097-0142(19821101)50:9<1888::aid-cncr2820500940>3.0.co;2-k

Cited by 68 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7, score 12). PR, peroxidase-antiperoxidase, original magnification × 200 Krumholz et al, 1973;Gloor et al, 1982;Baker et al, 1984;Tsukamoto et al, 1985;Keen and Philip, 1989;Montag and Manart, 1989;Rad and Lowe, 1990;Horowitz et al, 1996). Scribiner and Walker (1998) reported preoperative treatment of LGSS with progestins.…”

Section: Discussionmentioning

confidence: 92%

“…All four patients were alive and free of disease or alive with stable disease 2-6 years after initial diagnosis. Regression in size of metastases has been reported after bilateral oophorectomy (Baggish and Woodruff, 1972) and radiation-induced castration (Gloor et al, 1982). A lower incidence of recurrence and longer disease free intervals after bilateral oophorectomy have also been reported (Krieger and Gusberg, 1973).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

et al. 2000

View full text Add to dashboard Cite

We analysed oestrogen receptor (ER) and progesterone receptor (PR) expression in a retrospective series of 21 low-grade endometrial stromal sarcomas (LGSSs). Archival formalin-fixed and paraffin-embedded material was analysed by immunohistochemistry. ER and PR were measured with monoclonal antibodies and the peroxidase-antiperoxidase method and a score was calculated as for breast carcinoma based on both the percentage of positive tumour cell nuclei and the staining intensity. ER were seen in 15 (71%) and PR in 20 (95%) of tumours respectively. ER expression was scored as high in three (14%), moderate in four (19%), and low in eight (38%) tumours. Six (29%) tumours did not stain for ER and all of these were positive for PR. PR expression was scored as high in eight (38%), moderate in ten (47%) and weak in two (10%) LGSSs. Only one (5%) LGSS did not stain for PR (this tumour was positive for ER). ER and PR expression in LGSS is heterogeneous. This may have implications for hormone therapy in the management of these tumours. These results suggest that ER and PR should be routinely quantified in LGSSs by immunohistochemical methods. © 2000 Cancer Research Campaign

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

et al. 2000

View full text Add to dashboard Cite

show abstract

“…2 Similarly, shrinkage of metastases has been reported after bilateral oophorectomy and radiation-induced castration. 10,11 Krieger and Gusberg 12 reported a lower incidence of recurrence and longer disease-free survivals after bilateral oophorectomy.…”

Section: Discussionmentioning

confidence: 98%

Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study

2005

View full text Add to dashboard Cite

Gonadotropin-releasing hormone and its receptors have been identified in several human malignancies. We evaluated gonadotropin-releasing hormone receptor expression in 30 primary and recurrent endometrial stromal sarcomas. Archival formalin-fixed and paraffin-embedded material was analyzed immunohistochemically with antisera to gonadotropin-releasing hormone receptor type I and gonadotropin-releasing hormone receptor type II using the peroxidase-antiperoxidase method. Gonadotropin-releasing hormone receptor types I and II were demonstrated in most primary endometrial stromal sarcomas in varying intensity and percentage (range, 10-100%). The staining pattern was either diffuse cytoplasmic or granular/vesicular in perinuclear distribution. Recurrences stained stronger than primary tumors. The demonstration of gonadotropin-releasing hormone receptors I and II expression in endometrial stromal sarcomas may be a rationale for a clinical study of gonadotropin-releasing hormone analogs in the treatment of women with endometrial stromal sarcomas.

show abstract

“…We perform secondary and tertiary debulking surgery with organ resection and thoracotomies to tackle recurrent disease. Progestins (Gloor et al, 1982), gonadotropin-releasing agonists (Burke and Hickey, 2004) and aromatase inhibitors (Maluf et al, 2001;Leunen et al, 2004) are prescribed as systemic treatment in between the surgeries.…”

Section: Discussionmentioning

confidence: 99%

“…Endometrial stromal sarcoma development and/or recurrences can be induced by oestrogen-replacement therapy and tamoxifen (Beer et al, 1995;Chu et al, 2003), whereas progestins (Gloor et al, 1982), gonadotropin-releasing hormone analogues (Burke and Hickey, 2004) and aromatase inhibitors inhibit tumour growth (Maluf et al, 2001;Leunen et al, 2004). Recurrence rates in early-stage ESS are high (Chang et al, 1990), and the impact of surgical castration and adjuvant hormonal treatment needs to be investigated further.…”

mentioning

confidence: 99%

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

et al. 2007

View full text Add to dashboard Cite

The objective of this study is to assess the therapeutic importance of surgical castration, adjuvant hormonal treatment and lymphadenectomy in endometrial stromal sarcoma (ESS). A retrospective and multicentric search was performed. Clinicopathologic data were retrieved from cases that were confirmed to be ESS after central pathology review. The protocol was approved by the Ethical Committee. ESS was confirmed histopathologically in 34 women, but follow-up data were available in only 31 women. Surgical treatment (n ¼ 31) included hysterectomy with or without bilateral salpingo-oophorectomy (BSO) in 23 out of 31 (74%) and 8 out of 31 (26%) cases, respectively. Debulking surgery was performed in 6 out of 31 cases (19%). Stage distribution was as follows: 22 stage I, 4 stage III and 5 stage IV. Women with stage I disease recurred in 4 out of 22 (18%) cases. Among stage I women undergoing hormonal treatment with or without BSO, 3 out of 15 (20%) and 1 out of 7 (14%) relapsed, respectively. Among stages III -IV women receiving adjuvant hormonal treatment or not, 1 out of 5 (20%) and 3 out of 4 (75%) relapsed, respectively (differences ¼ 55.0%, 95% CI ¼ À6.8 -81.2%). Kaplan -Meier curves show comparable recurrence rates for stage I disease without adjuvant hormonal treatment when compared to stages III -IV disease treated with surgery and adjuvant hormonal treatment. Furthermore, women taking hormones at diagnosis have a better outcome when compared to women not taking hormonal treatment. Three out of 31 (9%) patients had a systematic lymphadenectomy whereas 3 out of 31 (9%) had a lymph node sampling. In one case, obvious nodal disease was encountered at presentation. Isolated retroperitoneal recurrence occurred in 1 out of 31 (3%) of all cases and in 1 out of 8 (13%) recurrences. This single woman later also developed lung and abdominal metastases. Leaving lymph nodes in situ does not appear to alter the clinical outcome of ESS. Although numbers are low, the retrospective data suggest that the need for surgical castration (BSO) in premenopausal women with early-stage disease should be discussed with the patient on an individual basis. The data support the current practice in some centres to administer adjuvant hormonal treatment.

show abstract

Endolymphatic stromal myosis. Surgical and hormonal treatment of extensive abdominal recurrence 20 years after hysterectomy

Cited by 68 publications

References 22 publications

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma

Contact Info

Product

Resources

About